Gene therapy for advanced colorectal cancer (dMMR/MSI-H)
Part of Cancer, Digestive system clinical trials.
This trial tests a new gene therapy (HNF4α SrRNA) given through a vein for people with advanced colorectal cancer that has a specific genetic marker (dMMR or MSI-H). It's for those who have already tried standard treatments without success or couldn't take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have colorectal cancer that has spread or cannot be removed, and standard treatments (like chemo, targeted therapy, or immunotherapy) are no longer working or you cannot take them.
- Your tumor has a specific genetic marker called dMMR or MSI-H (a type of mismatch repair deficiency).
- You have at least one tumor that can be measured on a scan.
- You are generally well enough to be up and about (able to do light activities) and not needing bed rest more than half of the day.
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a new experimental drug (HNF4α srRNA) given through a vein for people with advanced colorectal cancer that has not responded to or cannot be treated with standard therapies. The goal is to see if this treatment can help shrink or slow the growth of the cancer.
This trial tests a new treatment using special stem cells (modified to boost your immune system) for people with advanced colorectal cancer. It is for patients who are 18 or younger and whose cancer has not responded to or cannot be treated with standard therapies.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This trial tests whether using a simple blood test (ctDNA) can help guide treatment with immunotherapy drugs (PD-1 inhibitors) for people with a specific type of colon cancer (MSI-high/dMMR). The goal is to see if this approach can improve outcomes and reduce side effects compared to standard care.
Hear when a new Metastatic Colorectal Cancer (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.